BRPI0606281A2 - compostos orgánicos - Google Patents

compostos orgánicos

Info

Publication number
BRPI0606281A2
BRPI0606281A2 BRPI0606281-4A BRPI0606281A BRPI0606281A2 BR PI0606281 A2 BRPI0606281 A2 BR PI0606281A2 BR PI0606281 A BRPI0606281 A BR PI0606281A BR PI0606281 A2 BRPI0606281 A2 BR PI0606281A2
Authority
BR
Brazil
Prior art keywords
kinase
serine
compounds
organic compounds
threonine
Prior art date
Application number
BRPI0606281-4A
Other languages
English (en)
Inventor
Lawrence Blas Perez
Tao Sheng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0606281A2 publication Critical patent/BRPI0606281A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

COMPOSTOS ORGáNICOS. A presente invenção refere-se a compostos que são úteis para inibir, regular e/ou modular proteínas de tirosina e serina/treonina cinase e semelhantes à cinase, tal como RAF cinase, uma serina/treonina cinase que funciona na trilha de sinalização de MAP cinase. O pedido de patente é também concernido com composições que contêm estes compostos, e métodos de empregá-las para tratar doenças dependentes de tirosina e serina/treonina cinase e semelhantes à cinase, tais como angiogênese, câncer e hipertrofia cardíaca, e com outras matérias objeto.
BRPI0606281-4A 2005-03-17 2006-03-17 compostos orgánicos BRPI0606281A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66288905P 2005-03-17 2005-03-17
PCT/US2006/009713 WO2006102079A1 (en) 2005-03-17 2006-03-17 N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase

Publications (1)

Publication Number Publication Date
BRPI0606281A2 true BRPI0606281A2 (pt) 2009-06-09

Family

ID=36587426

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606281-4A BRPI0606281A2 (pt) 2005-03-17 2006-03-17 compostos orgánicos

Country Status (11)

Country Link
US (1) US20090306107A1 (pt)
EP (1) EP1871773A1 (pt)
JP (1) JP2008533172A (pt)
KR (1) KR20070113295A (pt)
CN (1) CN101175755A (pt)
AU (1) AU2006227447A1 (pt)
BR (1) BRPI0606281A2 (pt)
CA (1) CA2601766A1 (pt)
MX (1) MX2007011435A (pt)
RU (1) RU2007138264A (pt)
WO (1) WO2006102079A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110003859A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
CA2716951A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
JP2011513331A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
US20110003809A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
JP5819195B2 (ja) * 2008-10-16 2015-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合環ヘテロアリールキナーゼ阻害剤
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
JP6150813B2 (ja) 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
KR101660145B1 (ko) 2012-02-23 2016-09-26 다이호야쿠힌고교 가부시키가이샤 퀴놀릴피롤로피리미딜 축합환 화합물 또는 그의 염
EP2827868B8 (en) * 2012-03-19 2019-12-18 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
KR20150061651A (ko) 2012-09-26 2015-06-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ire1의 조절
TWI558706B (zh) * 2013-02-22 2016-11-21 Taiho Pharmaceutical Co Ltd A tricyclic compound and a tricyclic compound which can be produced by the production method
KR101906688B1 (ko) * 2013-08-22 2018-10-10 다이호야쿠힌고교 가부시키가이샤 신규 퀴놀린 치환 화합물
KR20180095595A (ko) * 2015-12-18 2018-08-27 노파르티스 아게 키나제 억제제로서의 트리시클릭 화합물 및 조성물
JOP20190073A1 (ar) 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
JP7341060B2 (ja) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
CN111465397B (zh) 2017-09-01 2023-10-13 大鹏药品工业株式会社 外显子18和/或外显子21突变型egfr的选择性抑制剂
JP7416716B2 (ja) 2017-12-28 2024-01-17 トラクト ファーマシューティカルズ インコーポレイテッド 円柱上皮幹細胞のための幹細胞培養系およびそれに関連した使用法
EP3960743A4 (en) * 2019-04-24 2022-05-04 Shanghai Institute of Materia Medica, Chinese Academy of Sciences PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, OPTICAL ISOMER THEREOF, METHOD OF PREPARATION THEREOF AND USE THEREOF
CN114478547A (zh) * 2020-10-23 2022-05-13 上海润石医药科技有限公司 固体形式的布鲁顿酪氨酸激酶抑制剂化合物及其用途
WO2022083745A1 (zh) * 2020-10-23 2022-04-28 中国科学院上海药物研究所 一种布鲁顿酪氨酸激酶抑制剂的用途
MX2023005747A (es) 2020-11-18 2023-07-28 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
CN113651755B (zh) * 2021-07-30 2022-07-29 山东师范大学 一种4-氮杂芴类化合物及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL32503A0 (en) * 1968-08-07 1969-08-27 American Cyanamid Co Pharmaceutical compositions containing pyridinium salts
US4022778A (en) * 1971-11-05 1977-05-10 American Home Products Corporation 10-Aryl-1,2,3,4-tetrahydropyrazino(1,2-α)indole and derivatives thereof
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
SK125999A3 (en) * 1997-03-19 2000-05-16 Knoll Ag Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
JPH11228572A (ja) * 1998-02-20 1999-08-24 Taisho Pharmaceut Co Ltd ４−（３−インドリル）イミダゾール誘導体
PL346700A1 (en) * 1998-09-18 2002-02-25 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors
PT1362047E (pt) * 2000-12-08 2006-09-29 Ortho Mcneil Pharm Inc Compostos de pirrolina substituidos com indazolilo como inibidores de cinase
EP1383771A1 (en) * 2001-04-20 2004-01-28 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
JP4279561B2 (ja) * 2001-05-23 2009-06-17 メルク フロスト カナダ リミテツド プロスタグランジンＤ２受容体拮抗薬としてのジヒドロピロロ［１，２−ａ］インドールおよびテトラヒドロピリド［１，２−ａ］−インドール誘導体

Also Published As

Publication number Publication date
CA2601766A1 (en) 2006-09-28
WO2006102079A1 (en) 2006-09-28
AU2006227447A1 (en) 2006-09-28
CN101175755A (zh) 2008-05-07
MX2007011435A (es) 2007-12-05
JP2008533172A (ja) 2008-08-21
RU2007138264A (ru) 2009-09-10
KR20070113295A (ko) 2007-11-28
US20090306107A1 (en) 2009-12-10
EP1871773A1 (en) 2008-01-02

Similar Documents

Publication Publication Date Title
BRPI0606281A2 (pt) compostos orgánicos
WO2007109045A8 (en) Heterocyclic organic compounds for the treatment of in particular melanoma
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
HN2012002664A (es) Compuestos, composiciones de tioacetato y metodos de uso
DOP2007000051A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
EA201101341A1 (ru) Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе
CL2007002492A1 (es) Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras.
BR112013003864A2 (pt) compostos de pirrolpirimidina e usos dos mesmos
GEP20156251B (en) Compounds and methods for kinase modulation, and indications therefor
BR112015028017A2 (pt) composto, composição farmacêutica, e, uso de um composto
CO6602158A2 (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
BRPI0712816B8 (pt) compostos de pirrolpirimidina e seus usos
ECSP17061751A (es) Nuevas proteínas específicas para pioverdina y pioquelina
PA8719401A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
GT201000376A (es) Compuestos organicos
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
ATE469151T1 (de) Pyrrolopyridinderivate als proteinkinaseinhibitoren
BR112012000968A8 (pt) Composto, composição e método para inibir uma fosfatidil inositol-3 cinase.
BRPI0609121B8 (pt) 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2
BR112013021236A2 (pt) composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
BRPI0720270B8 (pt) compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida
UY29458A1 (es) Heterociclos sustituidos y usos de los mismos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.